What is the prevalence of Biotinidase Deficiency?

Biotinidase deficiency is a rare metabolic disorder with an estimated global incidence of approximately 1 in 60,000 for profound deficiency and 1 in 40,000 for partial deficiency. While exact prevalence numbers are difficult to determine due to variations in newborn screening programs, the condition is considered a rare but treatable metabolic disease affecting both males and females equally.

How common is Biotinidase deficiency?

Biotinidase deficiency is classified as a rare disease. Because many regions have implemented universal newborn screening, the estimated incidence is better understood than its total prevalence. Data from the NIH GARD indicates that approximately 1 in 60,000 newborns worldwide are born with profound Biotinidase deficiency, where enzyme activity is less than 10% of normal levels. Including partial cases, the frequency is often cited as 1 in 40,000. Within our own DiseaseMaps.org community, 14 members have shared their experiences, offering a unique, real-world perspective on living with this diagnosis.

Does Biotinidase deficiency affect specific populations?

Biotinidase deficiency does not show a clear predilection for any specific ethnic or geographic group, though founder effects have been noted in some isolated populations. The condition is inherited in an autosomal recessive pattern, meaning both parents must carry a mutation in the BTD gene. Biotinidase deficiency affects males and females with equal frequency, as the gene is located on chromosome 3, not the sex chromosomes.

What challenges impact accurate prevalence data?

Several factors complicate our ability to track the exact number of people living with Biotinidase deficiency:

• Underdiagnosis: In countries without newborn screening, individuals with milder (partial) forms may remain undiagnosed until adulthood.


• Misdiagnosis: Symptoms of Biotinidase deficiency—such as seizures, skin rashes, and developmental delays—can be misattributed to other neurological or dermatological conditions.


• Variable Phenotypes: Because the severity of Biotinidase deficiency exists on a spectrum, some asymptomatic individuals may never seek clinical evaluation.

At what age does Biotinidase deficiency typically appear?

While Biotinidase deficiency is most commonly identified via newborn screening, the age of onset can vary significantly. Untreated infants typically present with symptoms within the first few months to years of life. However, late-onset cases in older children or even adults have been documented, particularly in those with partial Biotinidase deficiency who may only develop symptoms during periods of physiological stress.

Next steps

• Consult a metabolic specialist or geneticist to review your newborn screening results or diagnostic testing.


• Connect with the 14 members of the DiseaseMaps.org community to share experiences and coping strategies.


• Ensure regular follow-up with a metabolic dietician to manage biotin supplementation effectively.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Biotinidase Deficiency.


• Orphanet: Biotinidase deficiency (ORPHA:121).


• OMIM (Online Mendelian Inheritance in Man): Biotinidase Deficiency; BTD.


• National Organization for Rare Disorders (NORD): Biotinidase Deficiency.